
    
      All patients failing to enroll in a specific therapeutic research protocol using FDA approved
      drugs or CTMS accepted therapies will be screened for this study. Patients will be randomized
      (Patient own choice) to either standard of care described in the NCCN guidelines and
      published as peer-reviewed phase II or III studies which show an efficacy or to one of the
      arms of the protocol they fail to enroll in, as determined by the treating physician.
    
  